Celcuity Inc. - 8-K Filing
Celcuity receives FDA approval for REVTORPYK (gedatolisib) to treat HR+/HER2-, PIK3CA wild-type locally advanced or metastatic breast cancer. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $CELC